Day: December 22, 2021

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

Written by Customer Service on December 22, 2021. Posted in Public Companies.

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical Affairs and Food Sanitation Council that advises the Ministry of Health, Labour and Welfare (MHLW) in Japan has decided to continue deliberations on the application for the manufacturing and marketing approval of aducanumab for the treatment of Alzheimer’s disease. The NDC is seeking additional data to be submitted as part of this process. The companies will continue to actively engage with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to agree on additional data requirements. Biogen and Eisai remain committed to bringing aducanumab to patients in Japan expeditiously. About ADUHELM® (aducanumab-avwa) injection 100 mg/mL...

Abeona Therapeutics Issues Letter to Shareholders

Written by Customer Service on December 22, 2021. Posted in Public Companies.

NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders. Dear fellow shareholders, We have never been closer to fulfilling our mission of providing novel gene and cell therapies to patients who currently have no approved treatment options as we continue to advance the EB-101 and ABO-102 pivotal studies toward completion to support two U.S. Biologics License Application (BLA) submissions. At the same time, we are continuing to make steady progress with other clinical and preclinical programs. As we end the calendar year 2021, it is important to reflect on all that we at Abeona have achieved over the last 12 months, and it is even more crucial to look ahead at the opportunities awaiting us...

DSS Provides Update on Expansion of Premier Packaging Subsidiary

Written by Customer Service on December 22, 2021. Posted in Public Companies.

New 105,000 sq. ft. facility more than doubles Premier’s capacity to produce sustainable fiber-based packaging solutions for a wide variety of consumer products ROCHESTER, N.Y., Dec. 22, 2021 (GLOBE NEWSWIRE) — DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company with nine operating business lines in diverse, high-growth industries, today announced the facility expansion of its Premier Packaging Corporation (“Premier” or “Premier Packaging”) subsidiary is nearing completion with operations expected to begin at the new facility on February 1, 2022. For over 25 years, Premier has been a market leader in providing solutions for paperboard packaging from consumer retail packaging and heavy mailing envelopes, to sophisticated custom folding cartons and complex 3-dimensional direct mail solutions. Premier’s...

Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

Written by Customer Service on December 22, 2021. Posted in Public Companies.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer (CMO) to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases. Dr. Reinhart has been with the company since inception, first as an advisor and since 2017, as Chief Medical Officer responsible for the autoimmune and infectious diseases portfolio. “Harald has played a pivotal role in building Zai Lab’s broad and deep pipeline in autoimmune, infectious diseases and neuroscience,” said Dr. Samantha Du, Founder, Chairperson and CEO at Zai Lab. “This promotion not only recognizes Harald’s...

ECM Market Rising at 14.3% CAGR to Reach USD 29.64 billion by 2028 : Fortune Business Insights

Written by Customer Service on December 22, 2021. Posted in Mergers And Acquisitions.

Companies Profiled in Enterprise Content Management Market: Xerox Corporation, IBM Corporation, Microsoft Corporation, OpenText Corporation, Epicor Software Corp., Adobe Inc., Hyland Software, Inc., Fabasoft, Laserfiche, Datamatics Global Services Limited and others Pune, India, Dec. 22, 2021 (GLOBE NEWSWIRE) — The global ECM market size is expected to reach USD 29.64 billion by 2028, exhibiting a CAGR of 14.3% during the forecast period. The growing integration of artificial intelligence (AI) and machine learning (ML) in platforms will have an excellent impact on the market growth in the foreseeable future, states Fortune Business Insights, in a report, titled “Enterprise Content Management (ECM) Market, 2021-2028.” The market size stood at USD 10.33 billion in 2020. Request a Sample Copy of Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/enterprise-content-management-ecm-market-101660 The...

ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.

Written by Customer Service on December 22, 2021. Posted in Public Companies.

AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients. Fatality in hospital patients is associated with higher serum levels of ORF8. ORF8 is one of the least well conserved and most variable parts of the SARS-CoV-2 genome. “It is gratifying to identify what we think is the fundamental evolutionary pathway for SARS-CoV-2,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The analysis allows us to position...

Plato Gold Corp. Announces Closing of Non-Brokered Private Placement for $150,000

Written by Customer Service on December 22, 2021. Posted in Public Companies.

NOT FOR DISSEMINATION IN THE UNITED STATES OR OVER UNITED STATES NEWSWIRE SERVICES Toronto, Ontario, Dec. 22, 2021 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) is pleased to announce that further to its news release dated December 1, 2021, it has completed a non-brokered private placement for aggregate gross proceeds of $150,000 (the “Offering”). The Offering consisted of 3,000,000 common shares (“Shares”) at a price of $0.05 per Share. The proceeds raised from the sale of the Common Shares will be used for exploration expenses and general working capital purposes on the Company’s properties. Certain insiders of the Company subscribed, directly or indirectly, for an aggregate of 1,500,000 common shares pursuant to the Offering. Such participation is considered...

Calavo Growers, Inc. Appoints Brian W. Kocher President and CEO

Written by Customer Service on December 22, 2021. Posted in Public Companies.

SANTA PAULA, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today announced it has appointed Brian W. Kocher as President and Chief Executive Officer of the company effective Feb. 1, 2022. “After conducting a thorough search, including interviews with several well qualified candidates, Brian Kocher was the clear choice of our Board of Directors to become the next President and Chief Executive Officer of Calavo Growers,” said Calavo Chairman J. Link Leavens. “Brian’s deep knowledge, expertise and operational leadership in the fresh produce industry as a CEO, COO and CFO make him uniquely qualified to lead Calavo forward and position our company for growth. We are delighted to welcome Brian to our talented team.” “I am...

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Written by Customer Service on December 22, 2021. Posted in Public Companies.

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that it will develop R-107 for the treatment of persistent pulmonary hypertension of the newborn (“PPHN”). PPHN is fatal in up to 50% of newborn patients with this disorder, with up to 20% of surviving patients developing long term impairments such as hearing deficit, chronic lung disease, and intracranial bleeding.1 Highlights PPHN is one of the main causes of neonatal morbidity and mortality. PPHN is a serious condition, in which a newborn’s lung vessels are not open wide enough, resulting in restricted blood flow and inability to absorb oxygen. One symptom is that the baby’s skin is blue. Inhaled nitric oxide (“iNO”)...

MediPharm Labs Receives Award for CBD Brand of the Year

Written by Customer Service on December 22, 2021. Posted in Public Companies.

Kind Awards 2021 CBD Brand of the YearKind Awards 2021 CBD Brand of the YearMediPharm Labs pharma-quality CBD dominant oil line has been awarded CBD Brand of the year by KIND Magazine. MediPharm Labs’ CBD products have seen steady revenue growth and notoriety in 2021, including on national television on an episode of CBC Marketplace.BARRIE, Ontario, Dec. 22, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has been awarded best CBD brand of the year by Kind Magazine. “MediPharm Labs is honoured to be selected as CBD Brand of the Year. The MediPharm CBD SKUs lead our wellness line of products which are produced to a pharmaceutical quality standard...

Day: December 22, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice